Industry News

Pharmaceutical Industry News

Fresh off a phase 3 win in biliary…

August 26th, 2026|Fierce Pharma|

Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she continues to defend the

Baxter has initiated a recall of…

August 26th, 2026|Fierce Pharma|

Baxter has initiated a recall of two products because of particulate matter and Vitruvias Therapeutics has recalled one lot of thyroid tablets because of their potential to be “superpotent."

As the leadership vacuum at the…

August 26th, 2026|Fierce Pharma|

As the leadership vacuum at the top of the FDA looks poised to close with President Donald Trump’s nominee pick for a replacement commissioner, the agency is reportedly weighing whether to add two new deputy

Teva is increasingly highlighting…

August 25th, 2026|Fierce Pharma|

Teva is increasingly highlighting its innovative drug bona fides these days, seeking to style itself as both a novel drug-producing biopharma and a generics powerhouse.

Bausch + Lomb has come up short in…

August 25th, 2026|Fierce Pharma|

Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry-eye disease drugs Xiidra and Miebo. While the study missed its primary endpoint, the Ontario eye care specialist has

The healthcare conglomerate ,which…

August 25th, 2026|Fierce Pharma|

The healthcare conglomerate ,which ranks eighth on the Fortune 500 list, is set to envelope privately held Precision Medicine Group into its oncology branch as part of an ongoing effort to grow it's high-margin cancer

Sixteen months after Johnson &…

August 25th, 2026|Fierce Pharma|

Sixteen months after Johnson & Johnson scored its initial FDA approval for Imaavy, the pharma giant has tacked on a label expansion for the monoclonal antibody. The U.S. regulator has signed off on Imaavy to

The partnership builds on previous…

August 24th, 2026|Fierce Pharma|

The partnership builds on previous work and will expand Lundbeck's use of Eversana's AI Agency platform across its U.S. commercial organization, the companies said.

Frontier Large Language Models…

August 24th, 2026|Fierce Pharma|

Frontier Large Language Models have improved. More data became accessible. Neither solved the hardest questions. Here's what decision-grade pharma AI still needs.

The campaign adds older adults to…

August 24th, 2026|Fierce Pharma|

The campaign adds older adults to the obesity conversation and is anchored by Lilly's "A Life Covered" short film, which highlights a woman's decades-long weight loss journey.

Courts in Maryland and Washington,…

August 24th, 2026|Fierce Pharma|

Courts in Maryland and Washington, D.C., have rejected separate lawsuits by Merck and AstraZeneca against the Centers for Medicare & Medicaid Services' drug price negotiation program.

With the FDA expected to weigh in…

August 24th, 2026|Fierce Pharma|

With the FDA expected to weigh in on its kidney transplant drug, imlifidase, shortly before year-end, Hansa Biopharma is mulling over its stock listing options in the U.S.

With its ascent seemingly…

August 24th, 2026|Fierce Pharma|

With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some tough new realities.

Daiichi Sankyo is promoting Ken…

August 24th, 2026|Fierce Pharma|

Daiichi Sankyo is promoting Ken Keller to lead a new globally integrated commercialization unit, putting the executive in charge of a key pillar of its push to become a top five oncology company by 2035.

Education and insight company…

August 21st, 2026|Fierce Pharma|

Education and insight company Community Health Media curates its content library by centering physicians as "the talent" and centering its content creation on insightful physician-led conversations.

Almost three years into his tenure…

August 21st, 2026|Fierce Pharma|

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”